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Comparison of symptomatic and functional responses
to vagus nerve stimulation in ANTHEM-HF, INOVATEHF, and NECTAR-HF
Inder S. Anand1*, Marvin A. Konstam2, Helmut U. Klein3, Douglas L. Mann4, Jeffrey L. Ardell5, Douglas D.
Gregory6, Joseph M. Massaro7, Imad Libbus8, Lorenzo A. DiCarlo8, John James E. Udelson2, Javed Butler9,
John D. Parker10 and John R. Teerlink11
1
Division of Cardiology, University of Minnesota, Minneapolis, MN, USA; 2The CardioVascular Center at Tufts Medical Center, Boston, MA, USA; 3Division of Cardiology,
University of Rochester Medical Center, Rochester, NY, USA; 4Center for Cardiovascular Research, Washington University School of Medicine, Saint Louis, MO, USA; 5UCLA
Neurocardiology Program of Excellence, University of California, Los Angeles, CA, USA; 6Clinical Cardiovascular Science Foundation, Boston, MA, USA; 7Department of
Biostatistics, School of Public Health, Boston University, Boston, MA, USA; 8LivaNova USA Incorporated, Houston, TX, USA; 9Department of Medicine, University of Mississippi
Medical Center, Jackson, MS, USA; 10University of Toronto, University Health Network, Toronto, Ontario, Canada; 11Section of Cardiology, San Francisco Veterans Affairs
Medical Center and School of Medicine, University of California, San Francisco, CA, USA

Abstract
Aims Clinical studies of vagal nerve stimulation (VNS) for heart failure with reduced ejection fraction have had mixed results
to date. We sought to compare VNS delivery and associated changes in symptoms and function in autonomic regulation therapy via left or right cervical vagus nerve stimulation in patients with chronic heart failure (ANTHEM-HF), increase of vagal tone
in heart failure (INOVATE-HF), and neural cardiac therapy for heart failure (NECTAR-HF) for hypothesis generation.
Methods and results Descriptive statistics were used to analyse data from the public domain for differences in proportions
using Pearson’s chi-square test, differences in mean values using Student’s unpaired t-test, and differences in changes of mean
values using two-sample t-tests.
Guideline-directed medical therapy recommendations were similar across studies. Fewer patients were in New York Heart Association 3, and baseline heart rate (HR) was higher in ANTHEM-HF. In INOVATE-HF, VNS was aimed at peripheral neural targets, using closed-loop delivery that required synchronization of VNS to R-wave sensing by an intracardiac lead. Pulse
frequency was low (1–2 Hz) because of a timing schedule allowing ≤3 pulses of VNS following at most 25% of detected R
waves. NECTAR-HF and ANTHEM-HF used open-loop VNS delivery (i.e. independent of any external signal) aimed at both central and peripheral targets. In NECTAR-HF, VNS delivery at 20 Hz caused off-target effects that limited VNS up-titration in a
majority of patients. In ANTHEM-HF, VNS delivery at 10 Hz allowed up-titration until changes in HR dynamics were conﬁrmed.
Six months after VNS titration, signiﬁcant improvements in both HR and HR variability occurred only in ANTHEM-HF. When
ANTHEM-HF and NECTAR-HF were compared, greater improvements from baseline were observed in ANTHEM-HF in standard
deviation in normal-to-normal R-R intervals (94 ± 26 to 111 ± 50 vs. 146 ± 48 to 130 ± 52 ms; P < 0.001), left ventricular ejection fraction (32 ± 7 to 37 ± 0.4 vs. 31 ± 6 to 33 ± 6; P < 0.05), and Minnesota Living with Heart Failure mean score (40 ± 14 to
21 ± 10 vs. 44 ± 22 to 36 ± 21; P < 0.002). When compared with INOVATE-HF, greater improvement in 6-min walk distance was
observed in ANTHEM-HF (287 ± 66 to 346 ± 78 vs. 304 ± 111 to 334 ± 111 m; P < 0.04).
Conclusions In this post-hoc analysis, differences in patient demographics were seen and may have caused the differential
responses in symptoms and function observed in association with VNS. Major differences in technology platforms, neural targets, VNS delivery, and HR and HR variability responses could have also potentially played a very important role. Further study
is underway in a randomized controlled trial with these considerations in mind.
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Introduction
Vagus nerve stimulation (VNS) is approved for the management of drug-refractory epilepsy1,2 and is currently in development to deliver autonomic regulation therapy (ART) for
patients with chronic heart failure and reduced ejection fraction (HFrEF).3
Cardiac function and homeostasis comprises processes
within the central nervous system as well as local circuit neurons for networked control within the peripheral nervous system. Network interactions occur within the local circuit
neural populations. These integrate activities, within and between peripheral ganglia and the central nervous system, for
reﬂex control of the heart (Figure 1).
VNS is delivered utilizing a system that includes an implantable pulse generator and an electrical lead that requires no
intraoperative mapping for placement around the cervical
vagus nerve (CVN).4–6 An external programming system is
used to change the generator’s settings for stimulating the
CVN through the lead (Figure 2). The functional biological effects of CVN activation using VNS are deﬁned by the various
axons that traverse the nerve interface. Vagus nerve afferent
activation centrally modulates efferent sympathetic and parasympathetic function centrally and has tonic and basal effects
that decrease excess sympathetic activation and excessive release of norepinephrine. The summative effects of these
modulations result peripherally in vasorelaxation through activation of the nitric oxide pathway.7 Vagus nerve efferent activation causes anti-adrenergic effects both within the
intrinsic cardiac nervous system and via pre-synaptic and
post-synaptic interactions at the end terminus.8 At the
myocyte level, increases in acetylcholine from muscarinic receptors reduce oxidative stress, increase contractile function,
improve calcium signalling function, and restore gene expression. At the same time, cholinergic trans-differentiation of
sympathetic neurons occurs, providing a protective role
against sympathetically mediated pathogenesis.9
VNS delivery, or ‘dosing’, comprises the combination of VNS
intensity (including pulse amplitude, duration, and frequency),
polarity, and duty cycle, which is a repeating cycle over time.
Each duty cycle comprises a period of stimulation (‘on-time’)
that begins the cycle, followed by a period of no stimulation
(‘off-time’) to end the cycle, and is measured by dividing the
duration of the on-time by the total cycle duration (i.e. on-time
plus off-time). The mode of delivery may be closed loop or
open loop. Closed-loop delivery occurs only in response to
the detection of an external stimulus, whereas open-loop delivery is not gated by any external stimulus as a trigger for delivery (Figure 3).
Numerous pre-clinical and early phase human studies have
tested the potential role of ART using VNS to improve HFrEF;
however, changes in heart rate, heart rate variability, symptoms, and function in association with VNS have shown inconsistent results in larger clinical studies to date.10 The

reasons for the observed differences in the published data
are unclear. We sought to compare the patient demographics
and methodologies for VNS delivery and analysed the symptomatic and functional outcomes reported in the AutoNomic
Regulation Therapy to Enhance Myocardial Function in Heart
Failure (ANTHEM-HF) Pilot,11 Increase of Vagal Tone in Heart
Failure (INOVATE-HF),12 and Neural Cardiac Therapy for Heart
Failure (NECTAR-HF)13 studies to understand whether any of
these might explain the differences for hypothesis
generation.
All three of these contemporary studies conformed to the
principles outlined in the Declaration of Helsinki, and the
study protocols were approved by local ethics committees
at all of the study sites. All patients gave written informed
consent translated into local languages.

Methods
Information was obtained from peer-reviewed publications
and the public domain for descriptive analysis. Because
ANTHEM-HF was an uncontrolled trial, demographic data
and clinical outcomes for the treatment arms in these three
studies were used for comparisons. Descriptive statistics were
utilized to summarize observed differences in proportions
using Pearson’s chi-square test, differences in mean values
using Student’s unpaired t-test, and differences in changes of
mean values using two-sample t-tests with the Satterthwaite
approximation for different variances.14,15 Testing was performed at a signiﬁcance level of 0.05. No adjustment was
made for multiple comparisons. Given that only aggregate
data and not individual patient-level data were available to
the authors for INOVATE-HF and NECTAR-HF, statistical comparison between studies with respect to outcomes did not account for differences in baseline characteristics between the
studies. Because of small sample sizes of these studies, no
analysis was performed to assess non-inferiority of the
ANTHEM-HF results to the results of the other studies.

Results
The study designs4–6 and outcomes11–13 of the ANTHEM-HF
pilot, INOVATE-HF, and NECTAR-HF studies have been previously published.
Left ventricular ejection fraction (LVEF) ≤ 40% was required
to enroll in ANTHEM-HF and INOVATE-HF and ≤35% in
NECTAR-HF. New York Heart Association (NYHA) class 2 or 3
symptoms were required for entry into ANTHEM-HF and
NECTAR-HF, and NYHA 3 class symptoms were required for
INOVATE-HF. ANTHEM-HF randomized patients to VNS of
the left vs. right CVN and did not include a control arm.
INOVATE-HF and NECTAR-HF were randomized controlled
ESC Heart Failure 2020; 7: 76–84
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Figure 1 The intrinsic cardiac nervous system comprises sympathetic (Sympath) and parasympathetic (Parasym) efferent post-ganglionic neurons, local circuit neurons (LCN), and afferent (Aff.) neurons. The intrathoracic extracardiac nervous system is comprised of ganglia containing afferent neurons, LCN, and sympathetic efferent post-ganglionic neurons. Cardiovascular heart rate and demand inputs are conveyed centrally via dorsal root,
nodose and petrosal ganglia subserving spinal cord (C-cervical, T-thoracic), brainstem, and higher centre reﬂexes for haemostatic maintenance. From
Kember et al.26 (with permission).

trials that utilized VNS of the right CVN only. The recommendations for background HF therapy were similar for all three
studies. Unless treatment was contraindicated or intolerable,

patients were to receive beta-blockers, mineralocorticoid receptor antagonists (MRAs), digitalis, and an angiotensin
converting enzyme inhibitor or angiotensin receptor blocker
ESC Heart Failure 2020; 7: 76–84
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Figure 2 Open-loop vagal nerve stimulation (VNS) system to deliver autonomic regulation therapy (ANTHEM-HF, NECTAR-HF). For closed-loop VNS,
implantation of an additional intracardiac lead was used synchronize VNS to R-wave sensing (INOVATE-HF; see text).

Figure 3 Vagal nerve stimulation delivery includes its intensity (also called ‘dose’; a combination of pulse amplitude, pulse frequency, and pulse duration) and duty cycle.
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as background pharmacological treatment per guidelinedirected medical therapy (GDMT).
Table 1 summarizes treatment arm demographics by study.
When compared with patients in INOVATE-HF and NECTARHF, patients in ANTHEM-HF were younger and had a lower
body mass index and a higher baseline heart rate. Fewer patients were in NYHA Class 3. Baseline systolic blood pressure
was lower than in INOVATE-HF and trended lower than in
NECTAR-HF. There was a trend towards more beta-blocker
use in ANTHEM-HF when compared with the other two studies. More patients in ANTHEM-HF received MRAs than in
INOVATE-HF, and there tended to be more patients who received MRAs than in NECTAR-HF.
In ANTHEM-HF, the mean baseline LVEF was higher than in
INOVATE-HF, which required a lower baseline LVEF for study
entry, and there was no difference when compared with the
mean baseline LVEF in NECTAR-HF. The baseline 6-min walk
distance tended to be lower in ANTHEM-HF than in
INOVATE-HF. Six-minute walk tests were not performed in
NECTAR-HF.
Figure 4 illustrates how VNS was delivered, and Table 2
summarizes similarities and differences in VNS delivery by
study. Up-titration of VNS intensity was attempted in all three
studies. VNS delivery in ANTHEM-HF and NECTAR-HF was
open loop and was conﬁgured to direct stimulation in an afferent direction towards the CNS and in an efferent direction towards peripheral neural targets. In NECTAR-HF, VNS was
delivered at 20 Hz, which caused off-target adverse effects
that limited VNS up-titration in a majority of patients.13 In

ANTHEM-HF, VNS was delivered at 10 Hz and was well tolerated. Up-titration occurred in all patients in ANTHEM-HF until
autonomic modulation was conﬁrmed by a change in heart
rate dynamics.16
In contrast, VNS delivery was closed loop in INOVATE-HF,
which required the adjunct implantation of a right ventricular intracardiac lead in order to synchronize VNS delivery
to R-wave sensing.12 VNS was programmed using a timing
schedule that allowed no more than three pulses of VNS
following at most 25% of detected R waves.17,18 This resulted in a pulse frequency of 1–2 Hz, which was much
lower than the pulse frequencies used in ANTHEM-HF or
NECTAR-HF. VNS in INOVATE-HF also differed in being
aimed preferentially at peripheral neural targets, using
an asymmetric pulse delivery consisting of an initial
high-amplitude anodal phase to induce afferent
electrophysiologic conduction block followed by a lowamplitude cathodic phase to induce efferent electrophysiologic conduction. The current amplitude of the cathodic
phase was 5% of the current amplitude of the anodic
phase.12,18
Six months after completion of titration, heart rate decreased signiﬁcantly, and standard deviation in normal-tonormal R-R intervals (SDNN) increased signiﬁcantly in
ANTHEM-HF.11 Heart rate and SDNN were reported to be unchanged in INOVATE-HF and NECTAR-HF.12,13,22 Comparisons
of available data for symptomatic and functional outcomes
are summarized in Figure 5. When NECTAR-HF and
ANTHEM-HF were compared, greater improvements in heart

Table 1 Summary of treatment arm demographics by study

Age (years)
Male gender (%)
Ischaemic HF (% Patients)
NYHA 1/2/3/4 (%)
2
Body mass index (kg/m )
Systolic BP (mm Hg)
Heart rate (bpm)
LVEF (%)
6-min walk distance (m)
Beta-blockers (%)
ACEi or ARB (%)
MRA (%)
CRT (%)
CRT-D (%)
ICD (%)
Pacemaker (%)

ANTHEM-HF
N = 60

INOVATE-HF
N = 436

52 ± 12
87
75
0/57/43/0
24 ± 4
113 ± 15
78 ± 10
32 ± 7
287 ± 66
100
85
75
0
0
0
0

62 ± 10
78
59
0/0/100/0
30 ± 6
118 ± 17
73 ± 12
24 ± 7
304 ± 111
94
88
59
2
33
47
1

Differencea
[95% CI]
10 [ 12.2, 7.8]
9 [ 2.4, 16.6]
16 [3, 26]
c
c
57 [44, 69]
6 [ 7.6, 4.4]
5 [ 9.1, 0.8]
5 [1.8, 8.1]
8 [6.1, 9.8]
17 [ 46, 12]
6 [ 0.3, 8.6]
3 [ 14, 5]
16 [3, 26]
-

Pa

NECTAR-HF
N = 63

Differenceb
[95% CI]

Pb

<0.0001
0.11
<0.02
c
<0.0001
<0.0001
<0.02
0.0022
<0.0001
0.247
0.052
0.5
<0.02
-

60 ± 12
89
70
0/12/88/0
29 ± 6
118 ± 17
68 ± 13
31 ± 6
Unavailable
94
NR
68
0
5
51
NR

8 [ 12.2, 3.7]
2 [ 10, 14]
5 [ 10, 20]
c
c
45 [29, 58]
5 [ 6.8, 3.2]
5 [ 10.7, 0.7]
10 [5.8, 14.2]
1 [ 3.3, 1.3]
6 [ 1, 15]
7 [ 9, 22]
30c [21, 36]c
d
24 [12, 37]d
-

0.0003
0.73
0.5
c
<0.0001
<0.0001
<0.09
<0.0001
0.396
0.055
0.39
<0.0001c
<0.0001d
-

ACEi, angiotensin converting enzyme inhibitor; BP, blood pressure; CRT, cardiac resynchronization therapy; CRT-D, cardiac resynchronization
therapy with a deﬁbrillator; HF, heart failure; ICD, implantable cardioverter deﬁbrillator; LVEF, left ventricular ejection fraction; MRA,
mineralocorticoid receptor antagonist; NR, not reported; NYHA, New York Heart Association.
The remainder of the abbreviations are described in the text and the other tables. NN ± NN = mean ± standard deviation.
a
ANTHEM-HF vs. INOVATE-HF.
c
b
ANTHEM-HF vs. NECTAR-HF, with the exception of differences in electrical device implantations before randomization. Percentage of patients in NYHA 3.
c
INOVATE-HF vs. NECTAR-HF (any CRT).
d
INOVATE-HF vs. NECTAR-HF (any cardioverter-deﬁbrillator therapy).
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Figure 4 Differences in vagal nerve stimulation polarity, pulse frequency, and stimulation schedules across studies. A very complex repetitive schedule
of stimulation was utilized in increase of vagal tone in heart failure, as illustrated here and described in the text.

Table 2 Summary of vagal nerve stimulation delivery by study
ANTHEM-HF
Neural target
Delivery site
Delivery intensity
Amplitude (milliamperes)
Frequency (Hz)
Duration (ms)
Electrode polarity (cathode)
Duty cycle
On-time/off time (s)
Mode of delivery

Central/peripheral
Left or right CVN
a

2.0 ± 0.6
10
250
Caudal
23%
18/62
Open loop /cyclic

INOVATE-HF
peripheral
Right CVN
a

3.9 ± 1.0
b
1–2
500
Cephalad
25%
Variable
Closed loop /intermittent

NECTAR-HF
Central/peripheral
Right CVN
a

1.4 ± 0.8
20
300
Caudal
17%
10/50
Open loop / intermittent

CVN, cervical vagus nerve; a=mean ± standard deviation; b=range
The remainder of the abbreviations are described in the text and the other tables.

rate, SDNN, LVEF, and Minnesota Living with Heart Failure
(MLWHF) questionnaire mean score were observed in
ANTHEM-HF. When INOVATE-HF and ANTHEM-HF were compared, a greater improvement in 6-min walk distance was observed in ANTHEM-HF.

Discussion
In this post-hoc analysis, differences in some patient demographics were observed across the three studies. The GDMT
administered in ANTHEM-HF compared favorably with the
ESC Heart Failure 2020; 7: 76–84
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Figure 5 △ = difference; % = percent; bpm = beats per minute; 6MWD = six minute walk distance; EF = ejection fraction; HR = heart rate; Hz = Hertz; m
= meters; MLWHFS = Minnesota Living with Heart Failure Score; ms = milliseconds; SDNN = standard deviation of normal-to-normal RR intervals.

GDMT administered in INOVATE-HF, NECTAR-HF, and has also
compared favorably with other contemporary studies of
novel HF therapies for patients with HFrEF.19
The methodologies used for VNS in ANTHEM-HF, INOVATEHF, and NECTAR-HF differed considerably in their neurologic
targets, technology platforms, the mode and delivery of
VNS for ART, and the responses in heart rate and heart rate
variability that occurred in association with VNS.10,20,21
INOVATE-HF was a multinational, randomized, controlled
study of high amplitude, low-frequency VNS plus GDMT vs.
GDMT alone in 707 patients with chronic HF, NYHA 3 symptoms, and ejection fraction ≤ 40%. VNS delivery aimed preferentially at peripheral neural targets using closed-loop, lowfrequency, asymmetric pulses and was not associated with
any long-term change in mean heart rate or heart rate variability. The primary efﬁcacy endpoint of a composite of death
or HF hospitalization occurred more often in the VNS group
than in the control group but was not signiﬁcantly different.
Improvements occurred in the secondary endpoint outcomes
of NYHA class, Kansas City Cardiomyopathy Questionnaire
mean score, and 6-min walk distance.12
NECTAR-HF was a multicentre, randomized, shamcontrolled study of low-amplitude, high-frequency VNS plus
GDMT, vs. GDMT alone, in 96 patients with chronic HF,
NYHA Class 2 or 3, and ejection fraction ≤ 35%. The study
investigators reported that side effects (e.g. neck pain and
coughing) associated with a pulse frequency of 20 Hz limited titration to low stimulation amplitudes and resulted
in no signiﬁcant long-term reduction of heart rate or increase in heart rate variability. Whereas there were signiﬁcant improvements in MLWHF mean score, Short Form
Health Survey, and NYHA class after 6 months of followup, VNS did not reduce the primary efﬁcacy endpoint, LV
end-systolic diameter, or other secondary echocardiographic measures.13 A follow-up NECTAR-HF report presented results after 18 months of VNS in 96 patients with
the aim of evaluating long-term efﬁcacy of VNS at 20 Hz.

Although the long-term safety proﬁle was favourable, no
improvement in the efﬁcacy endpoints was seen with the
VNS dose that was delivered. A detailed analysis demonstrated that in the majority of patients, the VNS protocol
used in that study generated no signiﬁcant change in parameters of heart rate variability indicative of autonomic
modulation.22
The ANTHEM-HF pilot study was a multicentre uncontrolled study that randomized 60 patients with HFrEF to
VNS of the right or the left CVN. VNS delivery using 10 Hz,
and titration based upon conﬁrmation of autonomic engagement using changes in heart rate dynamics as a biomarker,
was associated with signiﬁcant improvements from baseline
in mean heart rate, heart rate variability (SDNN), LVEF, 6min walk distance, and MLWHF mean score.11,16
While VNS in ANTHEM-HF was associated with greater improvements in symptoms and function when compared with
VNS in INOVATE-HF and NECTAR-HF; any conclusions that
may be drawn should be considered hypothesis generating.
Data from the treatment arms was compared across three
studies because the ANTHEM-HF pilot study was an uncontrolled study. It is possible that the improvements in symptoms and function that were seen may not have been solely
attributable to ART alone or could have occurred due to a
Hawthorne effect, especially in the more subjective
assessments.
It is noteworthy that titration of VNS delivery ANTHEM-HF
resulted in an acute change in heart rate dynamics, and a
long-term decrease in heart rate and increase in heart rate
variability were observed only in that study. It is also encouraging that the overall direction of change that occurred in
symptoms and function after 6 months has also continued
in a cohort of ANTHEM-HF patients after 12, 24, and 42
months of VNS.23,24 Further study is underway in a randomized controlled trial with these considerations in mind. The
ongoing ANTHEM-HFrEF pivotal study is a multinational,
multicentre, randomized controlled trial evaluating the use
ESC Heart Failure 2020; 7: 76–84
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of ART in addition to GDMT to improve symptomatic and
functional outcomes and to decrease morbidity and
mortality.3

Conclusions
HFrEF is associated with sympatho-vagal imbalance consisting
of sustained sympathetic hyperactivation and withdrawal of
parasympathetic tone.25 Clinical studies that have administered VNS to deliver ART to patients with HFrEF have reported disparate responses in symptoms and function. In a
post-hoc analysis of the treatment arms of the ANTHEM-HF
pilot, INOVATE-HF, and NECTAR-HF studies, some differences
in patient demographics were observed and could have inﬂuenced the respective outcomes of these three studies. There
were also considerable differences in the technology platforms, neural targets, and delivery methods for VNS, and
these may have also had an important role in the relative
magnitudes of response to VNS that were observed in heart
rate, heart rate variability, symptoms, and function across
these studies. Further study is underway in a randomized
controlled trial with these considerations in mind.
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